Codexis Inc (NAS:CDXS)

$ 5 0.07 (1.42%) Market Cap: 406.89 Mil Enterprise Value: 358.48 Mil PE Ratio: 0 PB Ratio: 5.56 GF Score: 53/100

Q3 2024 Codexis Inc Earnings Call Transcript
Oct 31, 2024

$3.14 (-2.18%)

Earnings
Q2 2024 Codexis Inc Earnings Call Transcript
Aug 08, 2024

$3.15 (+4.30%)

Earnings
Q1 2024 Codexis Inc Earnings Call Transcript
May 02, 2024

$3.34 (+7.40%)

Earnings
Q4 2023 Codexis Inc Earnings Call Transcript
Feb 28, 2024

$3.72 (-10.36%)

Earnings
Codexis Inc To Provide Corporate Update Transcript
Feb 13, 2024
Codexis Inc to Host Virtual KOL Event Transcript
Dec 08, 2023
Q3 2023 Codexis Inc Earnings Call Transcript
Nov 02, 2023

$1.8 (+8.43%)

Earnings
Preliminary Q2 2023 Codexis Inc Earnings Call Transcript
Jul 20, 2023

$3.47 (+1.46%)

Earnings
Codexis Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Codexis Inc, Ginkgo Bioworks Holdings Inc and Twist Bioscience Corp at TD Cowen Health Care Conference- Panel Transcript
Mar 06, 2023
Q4 2022 Codexis Inc Earnings Call Transcript
Feb 23, 2023

$5.49 (-0.18%)

Earnings
Q3 2022 Codexis Inc Earnings Call Transcript
Nov 03, 2022

$5.71 (-0.70%)

Earnings
Q2 2022 Codexis Inc Earnings Call Transcript
Aug 04, 2022

$7.98 (+2.57%)

Earnings
Codexis Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2022
Codexis Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
May 24, 2022
Codexis Inc at UBS Global Life Science Conference (Virtual) Transcript
May 23, 2022
Q1 2022 Codexis Inc Earnings Call Transcript
May 05, 2022

$11.75 (-8.35%)

Earnings
Q4 2021 Codexis Inc Earnings Call Transcript
Feb 24, 2022

$19.38 (+12.02%)

Earnings
Codexis Inc at H C Wainwright Bioconnect Conference (Virtual) Transcript
Jan 10, 2022
Q3 2021 Codexis Inc Earnings Call Transcript
Nov 04, 2021

$34.96 (+3.43%)

Earnings
Q2 2021 Codexis Inc Earnings Call Transcript
Aug 05, 2021

$22.65 (+4.86%)

Earnings
Codexis Inc at UBS Global Healthcare Virtual Conference Transcript
May 24, 2021
Q1 2021 Codexis Inc Earnings Call Transcript
May 06, 2021

$19.82 (-2.65%)

Earnings
Codexis Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 04, 2021
Q4 2020 Codexis Inc Earnings Call Transcript
Feb 25, 2021

$21.24 (-7.21%)

Earnings
Q3 2020 Codexis Inc Earnings Call Transcript
Nov 05, 2020

$14.51 (+2.40%)

Earnings
Q2 2020 Codexis Inc Earnings Call Transcript
Aug 06, 2020

$12.85 (-0.16%)

Earnings
Codexis Inc Annual Shareholders Meeting Transcript
Jun 16, 2020
Codexis Inc at UBS Global Healthcare Conference (Virtual) Transcript
May 18, 2020
Q1 2020 Codexis Inc Earnings Call Transcript
May 07, 2020

$12.28 (+2.68%)

Earnings
Q4 2019 Codexis Inc Earnings Call Transcript
Feb 27, 2020

$13.27 (+2.23%)

Earnings
Q3 2019 Codexis Inc Earnings Call Transcript
Nov 05, 2019

$14 (+0.57%)

Earnings
Q2 2019 Codexis Inc Earnings Call Transcript
Aug 06, 2019

$16.99 (+2.04%)

Earnings
Codexis Inc at UBS Global Healthcare Conference Transcript
May 21, 2019
Q1 2019 Codexis Inc Earnings Call Transcript
May 06, 2019

$20.62 (+0.93%)

Earnings
Q4 2018 Codexis Inc Earnings Call Transcript
Feb 26, 2019

$21.95 (-0.59%)

Earnings

Codexis Inc at UBS Global Healthcare Conference Transcript

May 21, 2019 / 12:00PM GMT

Release Date Price: $19.02 (+1.49%)

Transcript

John J. Nicols

Codexis, Inc. - President, CEO & Director

Okay. Good morning. Thanks for starting your day off with Codexis. I am John Nicols. I'm the President and CEO of Codexis. I'm going to be making forward-looking statements today, so I encourage everyone to refer to our SEC filings most recent in early May.

Codexis, a 17-year-old company, entire history of the company has been focused on deploying a platform to discover novel proteins, to discover and commercialize novel proteins. We see it as an unlimited, untapped vast set of potential materials for the company to discover and bring to the world to add value to our clients. We've been creating proteins that enhance performance. We've been doing it in a growing list of industries. We're wielding a platform that is on the cutting edge of artificial intelligence against this particular dataset. And after 17 years, we've generated a very sustainable financial model based on multiple revenue-generation capabilities that we continue to deliver on working in parallel.

Some key challenges to protein discovery and commercialization.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.